{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T16:28:31Z","timestamp":1785601711379,"version":"3.56.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40271-019-00407-5","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T03:02:51Z","timestamp":1580353371000},"page":"317-325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient Perspective"],"prefix":"10.1007","volume":"13","author":[{"given":"Edouard","family":"Louis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Ramos-Go\u00f1i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Cuervo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Kopylov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Barreiro-de Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"McCartney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-8818","authenticated-orcid":false,"given":"Greg","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1435-4825","authenticated-orcid":false,"given":"Dominik","family":"Bettenworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailsa","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Donnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Easton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salda\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Protze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Tzur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Alperovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Casellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"issue":"9853","key":"407_CR1","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","volume":"380","author":"DC Baumgart","year":"2012","unstructured":"Baumgart DC, Sandborn WJ. Crohn\u2019s disease. Lancet. 2012;380(9853):1590\u2013605.","journal-title":"Lancet"},{"issue":"6","key":"407_CR2","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","volume":"140","author":"J Cosnes","year":"2011","unstructured":"Cosnes J, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785\u201394.","journal-title":"Gastroenterology"},{"key":"407_CR3","volume-title":"Robbins and Cotran pathologic basis of disease","author":"V Kumar","year":"2015","unstructured":"Kumar V, Abbas AK, Fousto N, Robbins SL, Cotran RS. Robbins and Cotran pathologic basis of disease. 9th ed. Philadelphia, PA: Saunders Elsevier; 2015.","edition":"9"},{"issue":"10114","key":"407_CR4","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2018","unstructured":"Ng SC, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769\u201378.","journal-title":"Lancet"},{"issue":"6","key":"407_CR5","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/apt.13940","volume":"45","author":"G Conway","year":"2017","unstructured":"Conway G, et al. The impact of co-existing immune-mediated diseases on phenotype and outcomes in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45(6):814\u201323.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"407_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/gastro\/gox005","volume":"6","author":"S Singh","year":"2018","unstructured":"Singh S, et al. Variations in the medical treatment of inflammatory bowel disease among gastroenterologists. Gastroenterol Rep (Oxf). 2018;6(1):61\u20134.","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"6","key":"407_CR7","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1007\/s12325-017-0545-4","volume":"34","author":"MF Kariburyo","year":"2017","unstructured":"Kariburyo MF, et al. Predicting pre-emptive discussions of biologic treatment: results from an openness and preference survey of inflammatory bowel disease patients and their prescribers. Adv Ther. 2017;34(6):1398\u2013410.","journal-title":"Adv Ther"},{"issue":"8","key":"407_CR8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jval.2012.08.2204","volume":"15","author":"K Stevens","year":"2012","unstructured":"Stevens K, Palfreyman S. The use of qualitative methods in developing the descriptive systems of preference-based measures of health-related quality of life for use in economic evaluation. Value Health. 2012;15(8):991\u20138.","journal-title":"Value Health"},{"issue":"7","key":"407_CR9","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.drudis.2019.05.001","volume":"24","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. Drug Discov Today. 2019;24(7):1324\u201331.","journal-title":"Drug Discov Today"},{"issue":"32","key":"407_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16320","volume":"16","author":"JE Brazier","year":"2012","unstructured":"Brazier JE, et al. Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome). Health Technol Assess. 2012;16(32):1\u2013114.","journal-title":"Health Technol Assess"},{"key":"407_CR11","unstructured":"US FDA. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims.2009 http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM193282.pdf. Accessed 1 May 2019."},{"issue":"8","key":"407_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, et al. Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2013eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967\u201377.","journal-title":"Value Health"},{"issue":"1","key":"407_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/ajg.2017.470","volume":"113","author":"CV Almario","year":"2018","unstructured":"Almario CV, et al. Optimizing selection of biologics in inflammatory bowel disease: development of an online patient decision aid using conjoint analysis. Am J Gastroenterol. 2018;113(1):58\u201371.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"407_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/01.MIB.0000437498.14804.50","volume":"20","author":"M Bewtra","year":"2014","unstructured":"Bewtra M, et al. Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis. 2014;20(1):103\u201314.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"407_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.dld.2016.09.009","volume":"49","author":"F Casellas","year":"2017","unstructured":"Casellas F, et al. Patient preferences for inflammatory bowel disease treatment objectives. Dig Liver Dis. 2017;49(2):152\u20136.","journal-title":"Dig Liver Dis"},{"key":"407_CR16","doi-asserted-by":"crossref","unstructured":"van Deen WK, N.D., Duran NE, Kane E, van Oijen MG, Hommes DW. Value redefined for inflammatory bowel disease patients: a choice-based conjoint analysis of patients\u2019 preferences. Quality of Life Research, 2017. 26(2): 455-465.","DOI":"10.1007\/s11136-016-1398-z"},{"issue":"3","key":"407_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40271-017-0294-0","volume":"11","author":"KJ Kamp","year":"2018","unstructured":"Kamp KJ, Brittain K. Factors that influence treatment and non-treatment decision making among individuals with inflammatory bowel disease: an integrative review. The Patient - Patient-Centered Outcomes Research. 2018;11(3):271\u201384.","journal-title":"The Patient - Patient-Centered Outcomes Research"},{"issue":"7","key":"407_CR18","doi-asserted-by":"publisher","first-page":"e0219905","DOI":"10.1371\/journal.pone.0219905","volume":"14","author":"M Trapero-Bertran","year":"2019","unstructured":"Trapero-Bertran M, Rodriguez-Martin B, Lopez-Bastida J. What attributes should be included in a discrete choice experiment related to health technologies? A systematic literature review. PLoS ONE. 2019;14(7):e0219905.","journal-title":"PLoS ONE"},{"key":"407_CR19","doi-asserted-by":"crossref","unstructured":"Cote-Daigneault, J., et al., Herpes zoster incidence in inflammatory bowel disease patients: a population-based study. Inflamm Bowel Dis, 2018.","DOI":"10.1093\/ibd\/izy311"},{"issue":"3","key":"407_CR20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jgh.14533","volume":"34","author":"SZ Huang","year":"2019","unstructured":"Huang SZ, et al. Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2019;34(3):507\u201316.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"407_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MIB.0000000000001033","volume":"23","author":"S Ghosh","year":"2017","unstructured":"Ghosh S, et al. Development of the IBD Disk: a visual self-administered tool for assessing disability in inflammatory bowel diseases. Inflamm Bowel Dis. 2017;23(3):333\u201340.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"407_CR22","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1177\/1049732312452938","volume":"22","author":"A Cooke","year":"2012","unstructured":"Cooke A, Smith D, Booth A. Beyond PICO: the SPIDER tool for qualitative evidence synthesis. Qual Health Res. 2012;22(10):1435\u201343.","journal-title":"Qual Health Res"},{"issue":"2","key":"407_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/136455700405172","volume":"3","author":"J Smithson","year":"2000","unstructured":"Smithson J. Using and analysing focus groups: limitations and possibilities. Int J Soc Res Methodol. 2000;3(2):103\u201319.","journal-title":"Int J Soc Res Methodol"},{"key":"407_CR24","unstructured":"National Health Council. FDA standard core clinical outcome assessments and endpoints (Notice No. NOT-FD-18-014). 2018. http:\/\/www.nationalhealthcouncil.org\/sites\/default\/files\/NHC%20Core%20Clinical%20Outcome%20Assessments%20Endpoints.pdf. Accessed 3 June 2019."}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-019-00407-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40271-019-00407-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-019-00407-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:10:28Z","timestamp":1611879028000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40271-019-00407-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["407"],"URL":"https:\/\/doi.org\/10.1007\/s40271-019-00407-5","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]},"assertion":[{"value":"30 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"AbbVie Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding:"}},{"value":"<i>E. Louis<\/i> has received consulting and\/or lecture fees from AbbVie, Ferring, MSD, Falk, Takeda, Hospira, Janssen, Pfizer, and Celgene; research grants from Takeda and Pfizer; and educational grants from AbbVie, Takeda, and Janssen; and has served on advisory boards for AbbVie, Ferring, MSD, Takeda, Celgene, Hospira, and Janssen. <i>J.M. Ramos<\/i>-<i>Go\u00f1i<\/i> has received consulting fees from AbbVie for conducting this research work. However, J.M. Ramos-Go\u00f1i does not have any conflict of interest with the results of this research. <i>J. Cuervo<\/i> has received consulting fees from AbbVie for conducting this research work. However, J. Cuervo does not have any conflict of interest with respect to the results of this research. <i>U. Kopylov<\/i> has received research grants from Janssen, Takeda, and Medtronic; speaker fees from Janssen, AbbVie, Takeda, MSD, and CTS; and advisory fees from Janssen, AbbVie, and Takeda. <i>M. Barreiro<\/i>-<i>de Acosta<\/i> has received financial support from AbbVie for this research. <i>S. McCartney<\/i> has received consulting, lecturing, or advisory board fees from AbbVie, Ferring, MSD, Falk, Takeda, and Janssen. <i>A. Hart<\/i> has served as consultant, advisory board member, or speaker for AbbVie, Atlantic, Bristol-Myers Squibb, Celltrion, Falk, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire, and Takeda. She also serves on the Global Steering Committee for Genentech. <i>G. Rosenfeld<\/i> has received financial support for research projects and speaking engagements, and consulting fees from several pharmaceutical companies. This support was not anticipated to impact this study. He also received support to enable him to attend the in-person meeting that formed a part of this study. <i>K. Novak<\/i> has received honoraria from AbbVie for participating in this research. <i>D. Easton<\/i> and <i>E. Tzur<\/i> have participated in AbbVie-sponsored research. <i>R. Salda\u00f1a<\/i> has not received any benefit from participating in this study. However, the patient association for which he works has received honoraria from AbbVie. <i>D. Bettenworth<\/i> is on the advisory board or has been a consultant for AbbVie, Amgen, Falk Foundation, Ferring, MSD, Pharmacosmos, Pfizer, Roche, Takeda, Tillotts Pharma, and Vifor. <i>X. Donnet<\/i> has received support for travel to meetings for this research study from AbbVie Inc. The non-profit patient association \u201cAssociation Crohn-RCUH\u201d, for which X. Donnet volunteers (as a Crohn patient), is sponsored by AbbVie, Dr Falk, Ferring, Janssen, Janssens, Pfizer, Takeda, and UCB. <i>K. Protze<\/i> has received consulting fees from AbbVie for participating in this research. However, K. Protze does not have any conflict of interest with respect to the results of this research. <i>F. Casellas<\/i> has received research funding from AbbVie, MSD, Shire, Ferring, and Zambon and speaker fees from AbbVie, MSD, Shire, Ferring, Zambon, Gebro, Chiesi, and Takeda. <i>G. Alperovich<\/i> is an AbbVie employee and may own AbbVie stock and\/or options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest:"}},{"value":"The authors and AbbVie scientists designed the research and analysed and interpreted the data. AbbVie funded the research and provided writing support. All authors contributed to the development of the content. The authors and AbbVie reviewed and approved the manuscript; the authors maintained control over the final content.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of authors and sponsor"}}]}}